Drugs / INO 5150
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02514213 | Jul 2015 → Dec 2017 | prostate cancer | Inovio Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO 5150 | “This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by...” NCT02514213 ↗ |
| Modality | Other / unclassified | “INO-5150 (DNA plasmids encoding prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA))” NCT02514213 ↗ |
| Route | Intramuscular | “delivered intramuscularly” NCT02514213 ↗ |